Group 1: Event Overview - The ninth China International Import Expo (CIIE) has officially launched its exhibition recruitment, with over 40 companies signing contracts, covering an exhibition area of 30,000 square meters [1] - The eighth CIIE has signed contracts for over 330,000 square meters of exhibition space, with 170 companies and 27 institutions recognized as "full attendance" participants [2] - The event will feature participation from 60 overseas exhibition groups from 40 countries and regions, with record-high participation from countries like Canada, Malaysia, New Zealand, Norway, and Peru, reflecting confidence in the Chinese economy [2] Group 2: Exhibitor Highlights - L'Oréal, a long-time exhibitor, will showcase new brands and technologies, marking the largest debut scale in its history, and will celebrate the 20th anniversary of its R&D center in China [6] - New Zealand's Fonterra will globally launch three new product categories, including "A2 Grass-fed Pure Milk," targeting the health-conscious Chinese consumer market [9][10] - Medtronic will present over 100 innovative medical technology products, including six global debuts, emphasizing the transformation of exhibition items into market products [20][24] Group 3: Innovation and New Products - The eighth CIIE will introduce a special area for products from least developed countries and a "cross-border e-commerce selection platform" [2] - Siemens Healthineers will showcase its largest exhibition area to date, featuring groundbreaking medical technologies such as the world's first life-sensing PET/MR system [20] - Abbott will debut its breakthrough cardiovascular technology, the Diamondback 360™ system, which aims to improve treatment reliability for coronary artery blockages [21]

Group 1 - Boston Scientific is confirmed as one of the first multinational medical companies to participate in the 9th China International Import Expo (CIIE) scheduled for 2026 [1] - The company aims to leverage the CIIE platform to better understand local clinical needs and accelerate the introduction of innovative products tailored to China's healthcare landscape [4][11] - Boston Scientific has a strong history of innovation, with over 10% of its revenue invested in R&D annually and multiple products recognized with prestigious awards [5] Group 2 - At the 8th CIIE, Boston Scientific will showcase over 80 innovative products, including five that will have their debut, addressing various clinical needs such as liver tumors and atrial fibrillation [7] - The company has successfully transitioned 22 products from exhibition to market approval in mainland China, demonstrating the effectiveness of the CIIE as a platform for commercialization [10] - The CIIE serves as a unique value proposition for connecting global innovations with China's clinical demands, acting as an accelerator for healthcare technology [11] Group 3 - The establishment of Boston Scientific's first manufacturing base in China, completed within a year, highlights the efficiency and speed of operations in the country, enhancing the company's local strategy [11] - The company emphasizes the importance of digitalization and precision in responding to the evolving healthcare needs in China, aligning with national health initiatives [11]